Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD 0332334 in Generalized Anxiety Disorder
NCT00921063Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2005
- Primary completion
- Jul 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of imagabalin in generalized anxiety disorder (GAD) (4 arms), sponsored by Pfizer. Primary endpoint: Hamilton Anxiety Rating Scale Total Score at 4 weeks. Started Nov 2005; status: completed.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00921063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921063.